Viroloxía e Patoxénese

ARTÍCULOS CIENTÍFICOS | SCIENTIFIC PAPERS | ARTIGOS CIENTÍFICOS

1. Poveda E, Crespo M. Hot News: Impact of Low-level Viremia on Treatment Outcomes During ART – Is it Time to Revise the Definition of Virological Failure? AIDS Rev. 2018;20(1):71–2. PMID: 29628513. http://www.ncbi.nlm.nih.gov/pubmed/29628513

2. Cid-Silva P, Margusino-Framiñán L, Balboa-Barreiro V, Martín-Herranz I, Castro-Iglesias Á, Pernas-Souto B, Llibre JM, Poveda E. Initial treatment response among HIV subtype F infected patients who started antiretroviral therapy based on integrase inhibitors. AIDS. 2018 Jan;32(1):121–5. PMID: 29112068. http://www.ncbi.nlm.nih.gov/pubmed/2911206

3. Grandal M, Pernas B, Tabernilla A, Mariño A, Álvarez H, Valcarce N, Mena A, Castro-Iglesias A, Pérez AB, Delgado M, Poveda E. Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies. J Med Virol. 2018 Jun;90(6):1094–8. PMID: 29427437. http://www.ncbi.nlm.nih.gov/pubmed/29427437

ARTÍCULOS CIENTÍFICOS | SCIENTIFIC PAPERS | ARTIGOS CIENTÍFICOS

1. Poveda E, Martin-Gayo E. Similar Immunological Profiles Between Nonprogressing HIV Infection in Children and Nonpathogenic SIV Infection. AIDS Rev. 2017;19(1):54–5. PMID: 28182614. http://www.ncbi.nlm.nih.gov/pubmed/28182614

2. Meijide H, Pértega S, Rodríguez-Osorio I, Castro-Iglesias Á, Baliñas J, Rodríguez-Martínez G, Mena Á, Poveda E. Increased incidence of cancer observed in HIV/hepatitis C virus-coinfected patients versus HIV-monoinfected. AIDS. 2017;31(8):1099–107. PMID: 28441174. http://www.ncbi.nlm.nih.gov/pubmed/28441174

3. Fernández-Caballero JA, Chueca N, Poveda E, García F. Minimizing Next-Generation Sequencing Errors for HIV Drug Resistance Testing. AIDS Rev. 2017;19(4):231–8. PMID: 28534892. http://www.ncbi.nlm.nih.gov/pubmed/28534892

4. Poveda E, Puoti M, García-Deltoro M, Pineda JA, Téllez F, Granados R, Morano L, García F. News on Viral Hepatitis in HIV: Update from the 2016 GEHEP Conference. AIDS Rev. 2017;19(1):47–53. PMID: 28182613. http://www.ncbi.nlm.nih.gov/pubmed/28182613

5. Poveda E, Freeman ML. Hot News: Exosomes as New Players in HIV Pathogenesis – New Data from the IAS 2017. AIDS Rev. 2017;19(3):173–5. PMID: 29019351. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5828156

6. Meijide H, Mena Á, Rodríguez-Osorio I, Pértega S, Castro-Iglesias Á, Rodríguez-Martínez G, Pedreira J, Poveda E. Trends in hospital admissions, re-admissions, and in-hospital mortality among HIV-infected patients between 1993 and 2013: Impact of hepatitis C co-infection. Enferm Infecc Microbiol Clin. 2017 Jan;35(1):20–6. PMID: 27609631. http://www.ncbi.nlm.nih.gov/pubmed/27609631

7. Meijide H, Mena Á, Rodríguez-Osorio I, Castro-Iglesias Á, Poveda E. Cancer Incidence in Persons Living With HIV. Clin Infect Dis. 2017 Feb;64(3):388–9. PMID: 28013260. http://www.ncbi.nlm.nih.gov/pubmed/28013260

8. Rodríguez-Osorio I, Cid P, Morano L, Castro Á, Suárez M, Delgado M, Margusino L, Meijide H, Pernas B, Tabernilla A, Pedreira JD, Mena Á, Poveda E. Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients. J Clin Virol. 2017 Mar;88:58–61. PMID: 28183063. http://www.ncbi.nlm.nih.gov/pubmed/28183063

9. Treviño A, Aguilera A, Rodríguez-Iglesias MA, Hernandez A, Benito R, Roc L, Ramos JM, Ortíz de Lejarazu R, Poveda E, Rodríguez C, Del Romero J, Calderon E, García J, Requena S, Soriano V, de Mendoza C. HTLV infection in HCV-antibody positive patients in Spain. AIDS Res Hum Retroviruses. 2017 Mar;33(10):1013–7. PMID: 28269998. http://www.ncbi.nlm.nih.gov/pubmed/28269998

10. Poveda E, Crespo M. When is Early Antiretroviral Therapy Early Enough for HIV Remission? AIDS Rev. 2017 Apr;19(2):113–4. PMID: 28534887. http://www.ncbi.nlm.nih.gov/pubmed/28534887

11. Tabernilla A, Grandal M, Pernas B, Castro-Iglesias A, Rodríguez-Osorio I, Mena A, Delgado M, Cid P, Pedreira JD, Poveda E. Short article: Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration. Eur J Gastroenterol Hepatol. 2017 Jul;29(7):781–5. PMID: 28410351. http://www.ncbi.nlm.nih.gov/pubmed/28410351

12. Grandal M, Pernas B, Mariño A, Álvarez H, Tabernilla A, Castro-Iglesias Á, Mena Á, Delgado M, Pértega S, Poveda E. Characterization of chronic HCV infection in Northwest Spain: Impact of the treatment strategic plan of the Spanish National Health Service on HCV cure. J Med Virol. 2017 Jul;89(7):1304–8. PMID: 28079256. http://www.ncbi.nlm.nih.gov/pubmed/28079256

13. de Mendoza C, Caballero E, Aguilera A, Requena S, de Lejarazu RO, Pirón M, González R, Jiménez A, Roc L, Treviño A, Benito R, Fernández-Alonso M, Aguinaga A, Rodríguez C, García-Costa J, Blanco L, Ramos JM, Calderón E, Eirós JM, Sauleda S, Barreiro P, Soriano V, Spanish HTLV Network. Human T-lymphotropic virus type 1 infection and disease in Spain. AIDS. 2017 Jul;31(12):1653–63. PMID: 28700391. http://www.ncbi.nlm.nih.gov/pubmed/28700391

14. Poveda E, Hernández-Quero J, Pérez-Elías MJ, Ribas MA, Martínez-Madrid OJ, Flores J, Navarro J, Gutiérrez F, García-Deltoro M, Imaz A, Ocampo A, Artero A, Blanco F, Bernal E, Pasquau J, Mínguez-Gallego C, Pérez N, Aiestaran A, García F, Paredes R, PROTEST study group. Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study. HIV Med. 2017 Aug;18(7):482–9. PMID: 28035758. http://www.ncbi.nlm.nih.gov/pubmed/28035758

15. Mena A, Meijide H, Rodríguez-Osorio I, Castro A, Poveda E. Liver-related mortality and hospitalizations attributable to chronic hepatitis C virus coinfection in persons living with HIV. HIV Med. 2017 Oct;18(9):685–9. PMID: 28230318. http://www.ncbi.nlm.nih.gov/pubmed/28230318

16. Cid-Silva P, Llibre JM, Fernández-Bargiela N, Margusino-Framiñán L, Balboa-Barreiro V, Pernas-Souto B, Martín-Herranz I, Castro-Iglesias Á, Poveda E. Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance. Basic Clin Pharmacol Toxicol. 2017 Nov;121(5):442–6. PMID: 28627771. http://www.ncbi.nlm.nih.gov/pubmed/28627771

17. Pernas B, Rego-Pérez I, Tabernilla A, Balboa V, Relaño S, Grandal M, Crespo M, Mena Á, Castro-Iglesias Á, Blanco FJ, Poveda E. Plasma mitochondrial DNA levels are inversely associated with HIV-RNA levels and directly with CD4 counts: potential role as a biomarker of HIV replication. J Antimicrob Chemother. 2017 Nov;72(11):3159–62. PMID: 28961892. http://www.ncbi.nlm.nih.gov/pubmed/28961892

ARTÍCULOS CIENTÍFICOS | SCIENTIFIC PAPERS | ARTIGOS CIENTÍFICOS

1. Tabernilla A, Rego-Pérez I, Grandal M, Pernas B, Pértega S, Delgado M, Mariño A, Álvarez H, Mena A, Rodríguez-Osorio I, Pedreira JD, Blanco FJ, Poveda E. Brief Report: European Mitochondrial Haplogroups Impact on Liver Fibrosis Progression Among HCV and HIV/HCV-Coinfected Patients From Northwest Spain. J Acquir Immune Defic Syndr. 2016;73(2):149–53. PMID: 27258234. http://www.ncbi.nlm.nih.gov/pubmed/27258234

2. Poveda E, Tabernilla A. New Insights into HIV-1 Persistence in Sanctuary Sites During Antiretroviral Therapy. AIDS Rev. 2016;18(1):55. PMID: 27028272. http://www.ncbi.nlm.nih.gov/pubmed/27028272

3. Pernas B, Grandal M, Tabernilla A, Cid P, Pértega S, Castro-Iglesias Á, Mena Á, Margusino L, Pedreira JD, Poveda E. Long-term clinical experience with darunavir (2007-2015) in a large cohort of HIV-infected patients in Spain. J Med Virol. 2016;88(12):2125–31. PMID: 27218208. http://www.ncbi.nlm.nih.gov/pubmed/27218208

4. Pernas B, Grandal M, Pertega S, Cañizares A, Castro-Iglesias Á, Mena Á, Rodriguez-Osorio I, Tabernilla A, Pedreira JD, Poveda E. Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART? J Antimicrob Chemother. 2016 Apr;71(4):1051–5. PMID: 26702924. http://www.ncbi.nlm.nih.gov/pubmed/26702924

5. Poveda E, Crespo M. New Strategies for a Comprehensive Fight Against HIV Infection using Monoclonal Antibody Therapy. AIDS Rev. 2016 Jul;18(3):166. PMID: 27721508. IF2016: 3.195; Q2. http://www.ncbi.nlm.nih.gov/pubmed/27721508

ARTÍCULOS CIENTÍFICOS | SCIENTIFIC PAPERS | ARTIGOS CIENTÍFICOS

1. Tabernilla A, Poveda E. The START Trial: Definitive Evidence to Treat All HIV-Positive Persons Regardless of CD4 Counts. AIDS Rev. 2015;17(3):187. PMID: 26450809. http://www.ncbi.nlm.nih.gov/pubmed/26450809

2. Poveda E. Discovery of a Natural Defense Against HIV With Therapeutic Potential. AIDS Rev. 2015;17(4):238. PMID: 26690492. http://www.ncbi.nlm.nih.gov/pubmed/26690492

3. Poveda E. HIV tropism shift: new paradigm on cell therapy strategies for HIV cure. AIDS Rev. 2015;17(1):65. PMID: 25608470. http://www.ncbi.nlm.nih.gov/pubmed/25608470

4. Treviño A, Caballero E, de Mendoza C, Aguilera A, Pirón M, Soriano V, Spanish HIV-2/HTLV Study Group. The Burden of Neglected HIV-2 and HTLV-1 Infections in Spain. AIDS Rev. 2015;17(4):212–9. PMID: 26616845. http://www.ncbi.nlm.nih.gov/pubmed/26616845

5. Paraskevis D, Kostaki E, Beloukas A, Cañizares A, Aguilera A, Rodríguez J, Grandal M, Pernas B, Castro-Iglesias A, Mena Á, Pedreira JD, Poveda E. Molecular characterization of HIV-1 infection in Northwest Spain (2009-2013): Investigation of the subtype F outbreak. Infect Genet Evol. 2015 Mar;30:96–101. PMID: 25527396. http://www.ncbi.nlm.nih.gov/pubmed/25527396

6. Pernas B, Mena A, Cañizares A, Grandal M, Castro-Iglesias A, Pértega S, Pedreira JD, Poveda E. Trends on epidemiological, virological, and clinical features among newly diagnosed HIV-1 persons in Northwest Spain over the last 10 years. J Med Virol. 2015 Aug;87(8):1319–26. PMID: 25777786. http://www.ncbi.nlm.nih.gov/pubmed/25777786

7. Poveda E, Wyles D, Morano L, Pineda JA, García F, Grupo de Estudio de Hepatitis Víricas (GEHEP), E P, D W, L M, JA P, F G, GEHEP. News on HIV-HCV coinfection: Update from the 2015 GEHEP conference. AIDS Rev. 2015 Oct;17(4):231–7. PMID: 26616846. IF2014: 3.787; Q2. http://www.ncbi.nlm.nih.gov/pubmed/26616846

8. Meijide H, Mena A, Marcos PJ, Rodriguez-Osorio I, Suárez-Fuentetaja R, Castro A, Poveda E, Pedreira JD. Lung cancer in patients living with HIV infection. AIDS. 2015 Nov;29(17):2363–4. PMID: 26544707. http://www.ncbi.nlm.nih.gov/pubmed/26544707

ARTÍCULOS CIENTÍFICOS | SCIENTIFIC PAPERS | ARTIGOS CIENTÍFICOS

1. Mena A, Moldes L, Meijide H, Cañizares A, Castro-Iglesias A, Delgado M, Pértega S, Pedreira J, Bou G, Poveda E. Seroprevalence of HCV and HIV infections by year of birth in Spain: impact of US CDC and USPSTF recommendations for HCV and HIV testing. PLoS One. 2014;9(12):e113062. PMID: 25436642. http://www.ncbi.nlm.nih.gov/pubmed/25436642

2. Poveda E, Pedreira JD. Highlights from CROI 2014 on experimental HIV drugs. AIDS Rev. 2014;16(2):118. PMID: 24984767. http://www.ncbi.nlm.nih.gov/pubmed/24984767

3. Poveda E. Ingenol derivates promising for HIV eradication. AIDS Rev. 2014;16(4):246. PMID: 25373349. http://www.ncbi.nlm.nih.gov/pubmed/25373349

4. Poveda E. Multi-step inhibition against HIV lifecycle-underlying the “magic” of protease inhibitors. AIDS Rev. 2014;16(1):52. PMID: 24589971. http://www.ncbi.nlm.nih.gov/pubmed/24589971

5. de Mendoza C, Caballero E, Aguilera A, Pirón M, Ortiz de Lejarazu R, Rodríguez C, Cabezas T, González R, Treviño A, Soriano V, Spanish HIV-2/HTLV Group. HIV-2 and HTLV-1 infections in Spain, a non-endemic region. AIDS Rev. 2014;16(3):152–9. PMID: 25180694. http://www.ncbi.nlm.nih.gov/pubmed/25180694

6. Monge S, Guillot V, Alvarez M, Chueca N, Stella N, Peña A, Delgado R, Córdoba J, Aguilera A, Vidal C, García F, CoRIS. Clinically relevant transmitted drug resistance to first line antiretroviral drugs and implications for recommendations. PLoS One. 2014;9(3):e90710. PMID: 24637804. http://www.ncbi.nlm.nih.gov/pubmed/24637804

7. Mena Á, Pedreira JD, Castro Á, López S, Vázquez P, Poveda E. Metabolic syndrome association with fibrosis development in chronic hepatitis B virus inactive carriers. J Gastroenterol Hepatol. 2014 Jan;29(1):173–8. PMID: 24219115. http://www.ncbi.nlm.nih.gov/pubmed/24219115

8. Garcia F, Poveda E, Pérez-Elías MJ, Quero JH, Ribas MA, Martínez-Madrid OJ, Flores J, Crespo M, Gutiérrez F, García-Deltoro M, Imaz A, Ocampo A, Artero A, Blanco F, Bernal E, Pasquau J, Mínguez-Gallego C, Pérez N, Aiestarán A, Paredes R. Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48-week analysis of the PROTEST study. J Int AIDS Soc. 2014 Jan;17(4 Suppl 3):19520. PMID: 25394029. IF: 5.090; Q1. http://www.ncbi.nlm.nih.gov/pubmed/25394029

9. Pernas B, Grandal M, Mena A, Castro-Iglesias A, Cañizares A, Wyles DL, López-Calvo S, Pértega S, Rodríguez-Osorio I, Pedreira JD, Poveda E. High prevalence of subtype F in newly diagnosed HIV-1 persons in northwest Spain and evidence for impaired treatment response. AIDS. 2014 Jul;28(12):1837–40. PMID: 24871456. http://www.ncbi.nlm.nih.gov/pubmed/24871456

10. Poveda E, Wyles DL, Mena A, Pedreira JD, Castro-Iglesias A, Cachay E. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res. 2014 Aug;108(1):181–91. PMID: 24911972. http://www.ncbi.nlm.nih.gov/pubmed/24911972

11. Treviño A, Soriano V, Poveda E, Parra P, Cabezas T, Caballero E, Roc L, Rodríguez C, Eiros JM, Lopez M, De Mendoza C, HIV-2 Spanish Study Group. HIV-2 viral tropism influences CD4+ T cell count regardless of viral load. J Antimicrob Chemother. 2014 Aug;69(8):2191–4. PMID: 24788659. http://www.ncbi.nlm.nih.gov/pubmed/24788659